- Home
- ENTA vs SSSS Comparison
ENTA vs SSSS Comparison
Compare ENTA & SSSS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ENTA
- SSSS
- Stock Information
- Founded
- ENTA 1995
- SSSS 2010
- Country
- ENTA United States
- SSSS United States
- Employees
- ENTA N/A
- SSSS N/A
- Industry
- ENTA Biotechnology: Pharmaceutical Preparations
- SSSS Finance: Consumer Services
- Sector
- ENTA Health Care
- SSSS Finance
- Exchange
- ENTA Nasdaq
- SSSS Nasdaq
- Market Cap
- ENTA 164.6M
- SSSS 138.2M
- IPO Year
- ENTA 2013
- SSSS N/A
- Fundamental
- Price
- ENTA $11.29
- SSSS $9.69
- Analyst Decision
- ENTA Strong Buy
- SSSS Strong Buy
- Analyst Count
- ENTA 6
- SSSS 4
- Target Price
- ENTA $20.83
- SSSS $9.50
- AVG Volume (30 Days)
- ENTA 1.5M
- SSSS 208.8K
- Earning Date
- ENTA 11-24-2025
- SSSS 11-06-2025
- Dividend Yield
- ENTA N/A
- SSSS 10.21%
- EPS Growth
- ENTA N/A
- SSSS N/A
- EPS
- ENTA N/A
- SSSS 2.22
- Revenue
- ENTA $64,806,000.00
- SSSS $2,784,381.00
- Revenue This Year
- ENTA $0.07
- SSSS $7,183.09
- Revenue Next Year
- ENTA N/A
- SSSS N/A
- P/E Ratio
- ENTA N/A
- SSSS $4.41
- Revenue Growth
- ENTA N/A
- SSSS N/A
- 52 Week Low
- ENTA $4.09
- SSSS $3.87
- 52 Week High
- ENTA $15.34
- SSSS $10.05
- Technical
- Relative Strength Index (RSI)
- ENTA 59.34
- SSSS 66.19
- Support Level
- ENTA $9.91
- SSSS $8.75
- Resistance Level
- ENTA $11.59
- SSSS $10.05
- Average True Range (ATR)
- ENTA 1.52
- SSSS 0.29
- MACD
- ENTA 0.19
- SSSS 0.06
- Stochastic Oscillator
- ENTA 52.96
- SSSS 68.85
About ENTA Enanta Pharmaceuticals Inc.
Enanta Pharmaceuticals Inc is an American biotechnology company which uses robust, chemistry-driven approach and drug discovery capabilities to focus on the research and development of molecule drugs to cure viral infections and liver diseases. Uses virology and immunology method for curing the diseases. The targeted diseases are hepatitis C, hepatitis B, nonalcoholic steatohepatitis, and the respiratory syncytial virus. The novelty of company research is a specific direct-acting antiviral inhibitor against the hepatitis C virus. The company's inhibitors have been developed in collaboration with AbbVie. AbbVie markets the protease inhibitor, paritaprevir, while other inhibitors are in the pipeline.
About SSSS SuRo Capital Corp.
SuRo Capital Corp is a non-diversified closed-end management investment company. The company's investment objective is to maximize its portfolio's total return, principally by seeking capital gains on its equity and equity-related investments.